|
|||||
|
|
The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System |
|
| Institution: | 1. Pharmaceutical Care Department, Medical Services for Armed Forces, Ministry of Defense, Riyadh, Saudi Arabia;2. Harvard T.H. Chan School of Public Health, Boston, MA, USA;3. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, USA;4. Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia;5. College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia |
| Abstract: | |
| Keywords: | COVID-19 Hydroxychloroquine Remdesivir QT prolongation FAERS |
| 本文献已被 ScienceDirect 等数据库收录！ | |